Abstract
BACKGROUND: Phakic intraocular lens (IOL) implantation is a common treatment for high myopia. However, pre- and postoperative psychological changes, particularly anxiety and depression, are noteworthy concerns. Multiple studies have indicated a close relationship between ophthalmic diseases, including high myopia, glaucoma, anxiety, and depression. AIM: To evaluate the impact of phakic IOL implantation on anxiety and depression in patients with high myopia. METHODS: Data from 136 patients with high myopia, who underwent phakic IOL implantation at the authors' hospital between June 2024 and December 2024, were retrospectively analyzed. Clinical data were collected from the hospital's electronic medical records system. Preoperative and one-month postoperative data were compared. Anxiety, depression, sleep quality, and quality of life were evaluated using the Hamilton anxiety scale, Hamilton depression scale, Pittsburgh Sleep Quality Index, and 36-item Short Form Health Survey, respectively. RESULTS: Of 136 patients, 67.65% (n = 92) were female and 32.35% (n = 44) were male, with a mean ± SD age of 28.02 ± 5.72 years. The mean uncorrected visual acuity before and 1 month after treatment was 1.83 ± 0.24 log minimum angle of resolution (MAR) and 0.03 ± 0.07 log MAR, respectively. The mean best corrected visual acuity before and 1 month after treatment was 0.04 ± 0.07 log MAR and 0.01 ± 0.02 log MAR, respectively. All differences were statistically significant (P < 0.05). Compared with pretreatment, Hamilton anxiety scale and Hamilton depression scale scores significantly decreased 1 month post-treatment (P < 0.05). Furthermore, the Pittsburgh Sleep Quality Index score was significantly lower after than that before treatment (P < 0.05). The 36-item Short Form Health Survey quality of life score significantly improved after treatment (P < 0.05). CONCLUSION: Phakic IOL implantation significantly reduces anxiety and depression and improves sleep quality and quality of life in patients with high myopia. This study provides new concepts for treating high myopia.